Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 20
Filter
1.
Nucleic Acids Res ; 42(17): 11040-55, 2014.
Article in English | MEDLINE | ID: mdl-25217584

ABSTRACT

Histone methylation changes and formation of chromatin loops involving enhancers, promoters and 3' end regions of genes have been variously associated with active transcription in eukaryotes. We have studied the effect of activation of the retinoic A receptor, at the RARE-promoter chromatin of CASP9 and CYP26A1 genes, 15 and 45 min following RA exposure, and we found that histone H3 lysines 4 and 9 are demethylated by the lysine-specific demethylase, LSD1 and by the JMJ-domain containing demethylase, D2A. The action of the oxidase (LSD1) and a dioxygenase (JMJD2A) in the presence of Fe++ elicits an oxidation wave that locally modifies the DNA and recruits the enzymes involved in base and nucleotide excision repair (BER and NER). These events are essential for the formation of chromatin loop(s) that juxtapose the RARE element with the 5' transcription start site and the 3' end of the genes. The RARE bound-receptor governs the 5' and 3' end selection and directs the productive transcription cycle of RNA polymerase. These data mechanistically link chromatin loops, histone methylation changes and localized DNA repair with transcription.


Subject(s)
Chromatin/chemistry , Histone Code , Transcription, Genetic , Tretinoin/pharmacology , Caspase 9/genetics , Chromatin/drug effects , Chromatin/enzymology , Cytochrome P-450 Enzyme System/genetics , DNA/metabolism , DNA Repair Enzymes/metabolism , Histone Code/drug effects , Histone Demethylases/metabolism , Histones/metabolism , Humans , MCF-7 Cells , Methylation/drug effects , Oxidation-Reduction , Promoter Regions, Genetic , RNA Polymerase II/metabolism , Receptors, Retinoic Acid/metabolism , Retinoic Acid 4-Hydroxylase , Transcription, Genetic/drug effects
2.
Protein Eng Des Sel ; 27(3): 83-8, 2014 Mar.
Article in English | MEDLINE | ID: mdl-24421342

ABSTRACT

The inhibition of ErbB2 by the use of human antibodies can be a valuable strategy for the treatment of breast and gastric cancer. Trastuzumab, a humanized anti-ErbB2 antibody in clinical use, is effective but can engender resistance as well as cardiotoxicity. ImmunoRNases, made up of a human anti-ErbB2 scFv and human pancreatic ribonucleases (HP-RNases), have been engineered to overcome the limits of other immunotoxins, such as immunogenicity and nonspecific toxicity. Here, we report that a novel anti-ErbB2 immunoRNase, called Erb-HPDDADD-RNase, obtained by fusing Erbicin, a human ErbB2-directed scFv, with an HP-RNase variant that resists the cytosolic inhibitor protein, binds with high affinity to a panel of ErbB2-positive gastric tumor cells and inhibits their growth more than does the parental immunoRNase, which is not resistant to the inhibitor. Moreover, Erb-HP-DDADD-RNase is endowed with antiproliferative activity for trastuzumab-resistant cancer cells both in vitro and in vivo that is more potent than that of the parental immunoRNase. Importantly, Erb-HP-DDADD-RNase does not show cardiotoxic effects in vitro on human cardiomyocytes and does not impair cardiac function in a mouse model. Thus, Erb-HP-DDADD-RNase could fulfil the therapeutic need of cancer patients ineligible for trastuzumab treatment due to primary or acquired trastuzumab resistance or to cardiac dysfunction.


Subject(s)
Antineoplastic Agents/pharmacology , Cardiotoxins/toxicity , Receptor, ErbB-2/chemistry , Recombinant Fusion Proteins/pharmacology , Recombinant Fusion Proteins/toxicity , Ribonuclease, Pancreatic/chemistry , Animals , Antibodies, Monoclonal, Humanized , Antineoplastic Agents/chemistry , Cardiotoxins/chemistry , Cell Line, Tumor , Cell Survival/drug effects , Humans , Mice , Myocytes, Cardiac/drug effects , Neoplasms, Experimental/pathology , Protein Engineering , Receptor, ErbB-2/genetics , Recombinant Fusion Proteins/chemistry , Recombinant Fusion Proteins/genetics , Ribonuclease, Pancreatic/genetics , Trastuzumab
3.
Gastric Cancer ; 17(1): 107-15, 2014 Jan.
Article in English | MEDLINE | ID: mdl-23460348

ABSTRACT

BACKGROUND: Gastric cancer represents one of the most common causes of cancer deaths worldwide. Overexpression of ErbB2, a tyrosine kinase receptor involved in the pathogenesis of several human cancer types, has been reported also in gastric cancer. Thus, the inhibition of ErbB2 signal transduction pathways by the use of human antibodies could be a valuable strategy for the therapy of this type of cancer. METHODS: We tested for the first time the antitumor effects on gastric cancer cells of Erb-hcAb, a novel fully human compact antibody, prepared in our laboratory, which targets a different epitope of ErbB2 with respect to trastuzumab, the only anti-ErbB2 antibody currently in clinical use for both breast and gastric cancer therapy. RESULTS: Herein we demonstrate that the in vitro and in vivo growth of gastric cancer cells is efficiently inhibited by Erb-hcAb, which shows antitumor effects on the NCI-N87 cell line more potent than those observed for trastuzumab. CONCLUSIONS: Erb-hcAb could be a promising candidate in the immunotherapy of gastric cancer as it combines the antiproliferative effect associated with the inhibition of ErbB2 signaling on tumor target cells with the ability to induce antibody-dependent cellular cytotoxicity.


Subject(s)
Antineoplastic Agents/pharmacology , Immunoconjugates/pharmacology , Molecular Targeted Therapy/methods , Receptor, ErbB-2/immunology , Receptor, ErbB-2/metabolism , Stomach Neoplasms/drug therapy , Animals , Antibodies, Monoclonal, Humanized/pharmacology , Cell Death/drug effects , Cell Line, Tumor , Cell Movement/drug effects , Cell Proliferation/drug effects , Female , Humans , Mice , Mice, Inbred BALB C , Signal Transduction/drug effects , Stomach Neoplasms/metabolism , Stomach Neoplasms/pathology , Trastuzumab , Xenograft Model Antitumor Assays
4.
PLoS One ; 7(4): e34405, 2012.
Article in English | MEDLINE | ID: mdl-22523549

ABSTRACT

Dual Oxidases (DUOX) 1 and 2 are efficiently expressed in thyroid, gut, lung and immune system. The function and the regulation of these enzymes in mammals are still largely unknown. We report here that DUOX 1 and 2 are expressed in human neuroblastoma SK-N-BE cells as well as in a human oligodendrocyte cell line (MO3-13) and in rat brain and they are induced by platelet derived growth factor (PDGF). The levels of DUOX 1 and 2 proteins and mRNAs are induced by reactive oxygen species (ROS) produced by the membrane NADPH oxidase. As to the mechanism, we find that PDGF stimulates membrane NADPH oxidase to produce ROS, which stabilize DUOX1 and 2 mRNAs and increases the levels of the proteins. Silencing of gp91(phox) (NOX2), or of the other membrane subunit of NADPH oxidase, p22(phox), blocks PDGF induction of DUOX1 and 2. These data unravel a novel mechanism of regulation of DUOX enzymes by ROS and identify a circuitry linking NADPH oxidase activity to DUOX1 and 2 levels in neuroblastoma cells.


Subject(s)
NADPH Oxidases/metabolism , Reactive Oxygen Species/metabolism , Animals , Cell Line, Tumor , Dual Oxidases , Humans , Neuroblastoma/metabolism , Platelet-Derived Growth Factor/pharmacology , RNA, Messenger/metabolism , Rats , Tumor Cells, Cultured
5.
Oncol Rep ; 28(1): 297-302, 2012 Jul.
Article in English | MEDLINE | ID: mdl-22505344

ABSTRACT

Prostate cancer is the most commonly diagnosed malignancy in men in developed countries. ErbB2, a tyrosine kinase receptor overexpressed in many human cancer types, contributes to prostate cancer progression by activating the androgen receptor in a steroid poor environment, thus promoting androgen-independent cell growth. The consequent development of hormone refractory tumors is a major obstacle in prostate cancer therapy. The inhibition of ErbB2 signal transduction pathways by the use of human antibodies could be a valuable alternative strategy for cancer therapy. We performed a comparative analysis in vitro and in vivo of the antitumor effects of three different antibodies targeting different epitopes of ErbB2: Herceptin (trastuzumab), 2C4 (pertuzumab) and Erb-hcAb (human anti-ErbB2-compact antibody), a novel fully human compact antibody produced in our laboratory. Herein, we demonstrate that the growth of both androgen-dependent and independent prostate cancer cells was efficiently inhibited by Erb-hcAb. The antitumor effects induced by Erb-hcAb on some cell lines were more potent than those observed for either Herceptin or 2C4. Thus, Erb-hcAb could be a promising candidate in the immunotherapy of prostate cancer for which no obvious treatment has been reported so far.


Subject(s)
Antibodies, Monoclonal, Humanized/pharmacology , Antineoplastic Agents/pharmacology , Prostatic Neoplasms/drug therapy , Recombinant Fusion Proteins/pharmacology , Animals , Antibodies, Monoclonal/metabolism , Antibodies, Monoclonal/pharmacology , Antibodies, Monoclonal, Humanized/metabolism , Antibodies, Monoclonal, Humanized/pharmacokinetics , Antibodies, Monoclonal, Humanized/therapeutic use , Antineoplastic Agents/pharmacokinetics , Antineoplastic Agents/therapeutic use , Cell Line, Tumor , Cell Survival/drug effects , Half-Life , Humans , Male , Mice , Mice, Inbred BALB C , Mice, Nude , Prostatic Neoplasms/metabolism , Protein Binding , Receptor, ErbB-2/metabolism , Recombinant Fusion Proteins/pharmacokinetics , Recombinant Fusion Proteins/therapeutic use , Tissue Distribution , Trastuzumab , Tumor Burden/drug effects , Xenograft Model Antitumor Assays
6.
Photomed Laser Surg ; 28 Suppl 1: S97-103, 2010 Aug.
Article in English | MEDLINE | ID: mdl-20666573

ABSTRACT

OBJECTIVE: Noninvasive in vivo imaging of human tumors implanted in mice provides a reliable and economic tool for the investigation of tumor progression and metastasis and of the effectiveness of the antiblastic drugs on them. The purpose of this study is to report on the performance achievable by the well-known and extensively investigated HP-FRI (HematoPorphyrin (HP)-mediated Fluorescence Reflectance Imaging) when a high-quality image-acquisition device is used. BACKGROUND DATA: Previous articles of ours showed that HP-FRI still represents a useful, simple and reliable optical imaging technique to detect surface tumors. Therefore, it is particularly suitable to be used in combination with other imaging modalities in a multimodal imaging system endowed with diagnostic capabilities much better than each separate modality. MATERIALS AND METHODS: Six-week-old Crl:CD-1 nude mice were subcutaneously inoculated with tumor cells. Tumor-bearing mice were irradiated in vivo by a frequency-doubled pulsed Nd:YAG laser (lambda = 532 nm). A cooled CCD digital camera recorded fluorescence light emitted by HP injected in mice through a cut-on long-wavelength pass filter. RESULTS: The system we developed allows in vivo imaging of surface tumors on small animals with a large field of view, high photometric sensitivity, adequate space resolution, and short measurement time. The estimated spatial resolution is 730 microm for a fluorescence source placed about 0.5 mm under the mouse skin. The first exploration of the capabilities of this HP-FRI setup on few mice shows that it allows the detection of (a) both types of investigated tumors, (b) early stage and late stage but visually unrecognizable tumors, (c) the gross structure of tumors, and (d) the discrimination of necrotic and nonnecrotic tumor regions.


Subject(s)
Early Detection of Cancer/methods , Hematoporphyrins , Neoplasms, Experimental/diagnosis , Photosensitizing Agents , Animals , Image Processing, Computer-Assisted , Lasers, Solid-State , Mice , Mice, Nude , Necrosis , Neoplasms, Experimental/pathology , Sensitivity and Specificity , Spectrometry, Fluorescence
7.
Endocr Relat Cancer ; 17(2): 373-82, 2010 Jun.
Article in English | MEDLINE | ID: mdl-20410173

ABSTRACT

Obesity is associated with an increased risk of breast cancer. A number of adipocytokines are increased in obesity causing low-level chronic inflammation associated with an increased risk of tumors. The adipocytokine leptin shows profound anti-obesity and pro-inflammatory activities. We have hypothesized that in common obesity, high circulating leptin levels might contribute to an increased risk of breast cancer by affecting mammary cell proliferation and survival. Leptin exerts its activity not only through leptin receptor (LepR), but also through crosstalk with other signaling systems implicated in tumorigenesis. In this study, we focused our attention on the relationship between the leptin/LepR axis and the estrogen receptor-alpha (ERalpha). To this aim, we utilized two human breast cancer cell lines, one ERalpha-positive cell line (MCF 7) and the other ERalpha-negative cell line (MDA-MB 231). We observed that the two cell lines had a different sensitivity to recombinant leptin (rleptin): on MCF 7 cells, rleptin induced a strong phosphorylation of the signal transducer and activator of transcription (STAT) 3 and of the extracellular related kinase 1/2 pathways with an increased cell viability and proliferation associated with an increased expression of ERalpha receptor. This response was not present in the MDA-MB 231 cells. The effects induced by leptin were lost when LepR was neutralized using either a monoclonal inhibitory antibody to LepR or LepR gene-silencing siRNA. These data suggest that there is a bidirectional communication between LepR and ERalpha, and that neutralization and/or inactivation of LepR inhibits proliferation and viability of human breast cancer cell lines. This evidence was confirmed by ex vivo studies, in which we analyzed 33 patients with breast cancer at different stages of disease, and observed that there was a statistically significant correlation between the expression of LepR and ERalpha. In conclusion, this study suggests a crosstalk between LepR and ERalpha, and could envisage novel therapeutic settings aimed at targeting the LepR in breast cancers.


Subject(s)
Breast Neoplasms/metabolism , Breast/metabolism , Carcinoma, Ductal, Breast/metabolism , Carcinoma, Lobular/metabolism , Estrogen Receptor alpha/metabolism , Receptors, Leptin/metabolism , Adult , Aged , Aged, 80 and over , Blotting, Western , Breast/drug effects , Breast Neoplasms/genetics , Carcinoma, Ductal, Breast/genetics , Carcinoma, Lobular/genetics , Cell Death/drug effects , Cell Line, Tumor , Cell Proliferation/drug effects , Cells, Cultured , Dose-Response Relationship, Drug , Estrogen Receptor alpha/genetics , Female , Gene Expression Regulation, Neoplastic , Humans , Immunohistochemistry , Leptin/metabolism , Leptin/pharmacology , Middle Aged , Mitogen-Activated Protein Kinase 3/metabolism , Neoplasm Staging , Phosphorylation/drug effects , Receptors, Leptin/genetics , STAT Transcription Factors/metabolism , Signal Transduction/drug effects , Statistics, Nonparametric
8.
Invest New Drugs ; 28(2): 115-23, 2010 Apr.
Article in English | MEDLINE | ID: mdl-19189054

ABSTRACT

The active components of Cannabis sativa and their derivatives produce a wide spectrum of effects, some of which may have clinical application. The discovery of specific cannabinoid receptors and a family of endogenous ligands of those receptors has attracted much attention to cannabinoids as agents capable of controlling the decision of cells to survive or die. We analysed the effects exerted by 2-methyl-2'-F-anandamide (Met-F-AEA), a metabolically stable analogue of anandamide, and observed a growth inhibition in cell lines derived from thyroid carcinomas. Growth inhibition was associated with a high level of CB1 receptor expression, suggesting that the cytotoxic effect is due to interaction with the CB1 receptor. This phenomenon was associated with activation of the protein, p53, an increased apoptotic rate, and expression of p21(CIP1/WAF1). This study provides new insights into the mechanism of Met-F-AEA action, and could have significance in providing a basis for the management of thyroid carcinoma.


Subject(s)
Apoptosis/drug effects , Arachidonic Acids/metabolism , Arachidonic Acids/pharmacology , Polyunsaturated Alkamides/metabolism , Thyroid Neoplasms/pathology , Cell Cycle Proteins/metabolism , Cell Line, Tumor , Cell Nucleus/drug effects , Cell Nucleus/metabolism , Cell Proliferation/drug effects , Drug Screening Assays, Antitumor , Endocannabinoids , Humans , Molecular Weight , Piperidines/pharmacology , Poly(ADP-ribose) Polymerases/metabolism , Pyrazoles/pharmacology , Receptor, Cannabinoid, CB1/antagonists & inhibitors , Receptor, Cannabinoid, CB1/metabolism , Rimonabant , Tumor Suppressor Protein p53/metabolism
9.
FASEB J ; 23(9): 3171-8, 2009 Sep.
Article in English | MEDLINE | ID: mdl-19417081

ABSTRACT

This study investigated potential cardiotoxicity as exerted by Erbicin-derived-immunoagents (EDIAs), novel human anti-ErbB2 immunoagents engineered by fusion of a human anti-ErbB2 scFv, Erbicin, with either a human RNase or the Fc region of a human IgG1. EDIAs are strongly cytotoxic on ErbB2-positive cells in vitro and in vivo and bind to an epitope different from that of Herceptin, a humanized anti-ErbB2 mAb effective in the therapy of breast carcinoma, but cardiotoxic in a high percentage of cases. Toxicity and apoptosis were tested in vitro by 3-(4,5-dimethyl-2-thizolyl)-2,5-diphenyl-2H-tetrazolium bromide (MTT), DNA fragmentation, and immunoblotting analyses. Echocardiography was measured in mice after treatment with each immunoagent. Cardiac fibrosis and detection of apoptosis were examined by Sirius red staining of collagen and TUNEL assay, respectively. EDIAs were found in vitro to have no adverse effects on cardiac cells for which Herceptin is severely toxic. In vivo studies on a mouse model showed that the EDIAs did not alter cardiac function, whereas Herceptin and doxorubicin, used as positive controls, significantly reduced the fractional shortening parameter. Cardiac fibrosis and apoptosis were not significantly affected in mice treated with EDIAs. Thus, EDIAs could fulfill the therapeutic need of patients ineligible for Herceptin treatment due to cardiac dysfunction.


Subject(s)
Antibodies, Monoclonal/therapeutic use , Receptor, ErbB-2/immunology , Animals , Antibodies, Monoclonal/pharmacology , Antibodies, Monoclonal/toxicity , Antibodies, Monoclonal, Humanized , Antineoplastic Agents/pharmacology , Antineoplastic Agents/toxicity , Apoptosis/drug effects , Breast Neoplasms/complications , Breast Neoplasms/drug therapy , Cardiotoxins , DNA Fragmentation/drug effects , Drug-Related Side Effects and Adverse Reactions , Electrocardiography , Fibrosis/chemically induced , Humans , Mice , Protein Engineering/methods , Trastuzumab
10.
Lasers Med Sci ; 24(2): 284-9, 2009 Mar.
Article in English | MEDLINE | ID: mdl-18324434

ABSTRACT

The in vivo early detection of subcutaneous human tumors implanted in small animals was studied by laser-induced fluorescence reflectance imaging (FRI), with a hematoporphyrin (HP) compound as an exogenous optical contrast agent. Tumor detection was shown to be possible just 3 days after the inoculation of tumor cells, when tumors were neither visible nor palpable. However, this detection capability is limited to a temporal window of approximately 100 h from HP administration and to a low optical contrast of the tumor (<2).


Subject(s)
Early Detection of Cancer , Hematoporphyrins , Image Processing, Computer-Assisted , Photosensitizing Agents , Skin Neoplasms/diagnosis , Animals , Cell Line, Tumor , Humans , Mice , Mice, Nude , Neoplasm Transplantation , Sensitivity and Specificity , Skin Neoplasms/etiology , Spectrometry, Fluorescence
11.
Carcinogenesis ; 26(11): 1890-5, 2005 Nov.
Article in English | MEDLINE | ID: mdl-15930029

ABSTRACT

ErbB2 is a prognostic factor and target of therapy for many carcinomas. In contrast with the other ErbB receptors, ErbB2 lacks a soluble direct ligand, but it is the preferred co-receptor for the ErbB family members, forming heterodimers with more potent and prolonged signalling activity than that of homodimers. We recently produced a new anti-ErbB2 antibody, Erb-hcAb, by fusion of Erbicin, a human, anti-ErbB2 scFv, selectively cytotoxic to ErbB2-positive cells, and a human Fc domain. This fully human antitumour antibody represents a compact version of an IgG1, with the cytotoxicity of the scFv moiety on target cells, combined with the ability of the Fc moiety to induce both antibody- and complement-dependent cytotoxicity. Here, we describe the main properties of Erb-hcAb, using as a reference Herceptin, an anti-ErbB2 humanized monoclonal currently employed in clinical immunotherapy. We found that both bivalent Erb-hcAb and Herceptin increase receptor phosphorylation and downregulation, whereas monovalent Erbicin does not. These results correlate with the finding that Erb-hcAb is capable of inducing apoptosis and inhibiting cell cycle progression in ErbB2-positive cells. Its powerful in vitro antitumour action matched that observed in vivo in experiments with human ErbB2-positive tumour xenografts established in athymic mice. Finally, Erb-hcAb displays a glycosylation profile virtually superimposable to that of a human IgG. These findings suggest that Erb-hcAb is a very promising new agent for the immunotherapy of carcinomas that overexpress the ErbB2 receptor.


Subject(s)
Antibodies, Monoclonal/pharmacology , Immunoglobulin Variable Region/immunology , Neoplasms, Experimental/prevention & control , Receptor, ErbB-2/immunology , Recombinant Fusion Proteins/pharmacology , Animals , Antibodies, Monoclonal/therapeutic use , Antibodies, Monoclonal, Humanized , Apoptosis , Cell Cycle/drug effects , Cell Line, Tumor/drug effects , Female , Humans , Immunoblotting , Immunoglobulin G/immunology , Mice , Mice, Inbred BALB C , Mice, Nude , Neoplasms, Experimental/immunology , Neoplasms, Experimental/pathology , Phosphorylation , Polymerase Chain Reaction , Recombinant Fusion Proteins/therapeutic use , Trastuzumab
12.
Carcinogenesis ; 26(4): 733-9, 2005 Apr.
Article in English | MEDLINE | ID: mdl-15661812

ABSTRACT

Astins, a family of cyclopentapeptides, isolated from the roots of a medicinal plant Aster tataricus (Compositae), show antitumour activity. Their chemical structures consist of a 16-membered ring system containing a unique beta,gamma-dichlorinated proline [Pro(Cl2)], other non-coded amino acid residues, and a cis conformation in one of the peptide bonds. The beta,gamma-dichlorinated proline residue is considered to play an important role in their antineoplastic activities in vitro on nasopharynx carcinoma (KB) cells and in vivo on sarcoma 180 ascites and P388 lymphocytic leukaemia in mice. The acyclic astins without Pro(Cl2) do not show antitumour activity against S-180 ascites in vivo, suggesting that the cyclic nature of astins plays an important role in their antitumour activities. We synthesized new astin-related cyclopeptides differing from the natural product for the presence of some non-proteinogenic amino acid residues: Aib, Abu, -S(beta3)-hPhe and a peptide bond surrogate (-SO2-NH-) and we tested for their antitumour effect. We observed cytotoxic effects of the newly synthesized cyclic astins, but not with the acyclic analogue astins. We also observed that the cyclic astin induced apoptosis in a human papillary thyroid carcinoma cell line (NPA cell line) and that apoptotis was associated with activation of caspases. The caspase family inhibitor, Z-Val-Asp-(OMe)-FMK, protected NPA cells from cyclic analogue astin-induced apoptosis. To determine which caspase was specifically activated, we assayed caspase activity in astin-treated cells in the presence of specific caspase and 8, 9 or 3 inhibitors, i.e. Z-IETD-FMK, Z-LEHD-FMK Z-DEVD-FMK, which inhibit caspases 8, 9 and 3, respectively. The data presented here show selective antineoplastic properties of the newly synthesized cyclic astins, and suggest, for the first time, a mechanism for their antineoplastic action through the activation of apoptotic pathway.


Subject(s)
Antineoplastic Agents/therapeutic use , Apoptosis/drug effects , Carcinoma, Papillary/pathology , Caspases/metabolism , Peptides, Cyclic/pharmacology , Thyroid Neoplasms/pathology , Aster Plant/chemistry , Carcinoma, Papillary/enzymology , Caspase Inhibitors , Cell Line, Tumor , Drug Screening Assays, Antitumor , Enzyme Activation/drug effects , Enzyme Inhibitors/pharmacology , Humans , Thyroid Neoplasms/enzymology
13.
J Clin Endocrinol Metab ; 90(2): 928-35, 2005 Feb.
Article in English | MEDLINE | ID: mdl-15562011

ABSTRACT

Alterations in chromosome number (aneuploidy) are common in human neoplasias. Loss of mitotic regulation is believed to induce aneuploidy in cancer cells and act as a driving force during the malignant progression. The serine/theronine protein kinases of aurora family genes play a critical role in the regulation of key cell cycle processes. Aurora B mediates chromosome segregation by ensuring orientation of sister chromatids and overexpression of Aurora B in diploid human cells NHDF (normal human diploid fibroblast) induces multinuclearity. We analyzed Aurora B expression in human thyroid carcinomas. Cell lines originating from different histotypes showed an increase in Aurora B expression. Immunohistochemical analysis of archive samples showed a high expression of Aurora B in anaplastic thyroid carcinomas; conversely, Aurora B expression was not detectable in normal thyroid tissue. Real-time PCR analysis confirmed a strong expression of Aurora B in anaplastic thyroid carcinomas. The block of Aurora B expression induced by RNA interference or by using an inhibitor of Aurora kinase activity significantly reduced the growth of thyroid anaplastic carcinoma cells.


Subject(s)
Protein Serine-Threonine Kinases/genetics , Thyroid Neoplasms/genetics , Animals , Aurora Kinase B , Aurora Kinases , Base Sequence , Carcinoma/enzymology , Carcinoma/genetics , Carcinoma/pathology , Cell Division , Cell Line, Tumor , DNA Primers , Gene Expression Regulation, Enzymologic , Gene Expression Regulation, Neoplastic , Humans , Mice , Mice, Nude , Phenotype , Reverse Transcriptase Polymerase Chain Reaction , Thyroid Neoplasms/enzymology , Thyroid Neoplasms/pathology , Transplantation, Heterologous
14.
Biopolymers ; 76(6): 477-84, 2004.
Article in English | MEDLINE | ID: mdl-15372484

ABSTRACT

The astins, a family of natural antitumor cyclopeptides, from the roots of Aster tataricus, consist of a 16-membered ring system containing uncoded amino acid residues. The backbone conformation, with a cis-3,4-dichlorinated proline residue, plays an important role in antineoplastic activity. The acyclic astins, on the other hand, do not show antitumor activity, suggesting that the cyclic nature of astins may be a key role in their biological properties. Although the antineoplastic activity of natural astins has been screened in vitro and in vivo, the mechanism of action has never been investigated. With the aim at elucidating the influence of conformational flexibility on biological activity, we have designed and synthesized several astin analogues containing either Aib and the nonproteinogenic Abu and (S)beta3-hPhe residues, able to modify the peptide backbone structure, or the peptide bond surrogate -SO2-NH-. Tested for their antitumor effect, our astin-related cyclopeptides are able to inhibit the growth of tumor cell lines, while the acyclic astins are inefficacious. The present work reports on the structure-activity study of a selected synthetic cyclotetrapeptide corresponding to the sequence c[Thr-Aib-(S)beta3-hPhePsi(CH2-SO2-NH)-Abu], synthesized by classical methods and characterized conformationally by two-dimensional NMR and molecular dynamics analyses.


Subject(s)
Peptides, Cyclic/chemistry , Peptides, Cyclic/pharmacology , Animals , Antineoplastic Agents, Phytogenic/chemistry , Antineoplastic Agents, Phytogenic/pharmacology , Aster Plant/chemistry , Models, Molecular , Nuclear Magnetic Resonance, Biomolecular , Protein Conformation
15.
Cancer Res ; 64(14): 4870-4, 2004 Jul 15.
Article in English | MEDLINE | ID: mdl-15256457

ABSTRACT

We report the preparation and characterization of a novel, fully human antitumor immunoRNase (IR). The IR, a human RNase and fusion protein made up of a human single chain variable fragment (scFv), is directed to the ErbB-2 receptor and overexpressed in many carcinomas. The anti-ErbB-2 IR, named hERB-hRNase, retains the enzymatic activity of the wild-type enzyme (human pancreatic RNase) and specifically binds to ErbB-2-positive cells with the high affinity (K(d) = 4.5 nm) of the parental scFv. hERB-hRNase behaves as an immunoprotoxin and on internalization by target cells becomes selectively cytotoxic in a dose-dependent manner at nanomolar concentrations. Administered in five doses of 1.5 mg/kg to mice bearing an ErbB-2-positive tumor, hERB-hRNase induced a dramatic reduction in tumor volume. hERB-hRNase is the first fully human antitumor IR produced thus far, with a high potential as a poorly immunogenic human drug devoid of nonspecific toxicity, directed against ErbB-2-positive malignancies.


Subject(s)
Immunotoxins/pharmacology , Receptor, ErbB-2/metabolism , Recombinant Fusion Proteins/pharmacology , Ribonucleases/pharmacology , Amino Acid Sequence , Animals , Breast Neoplasms/drug therapy , Breast Neoplasms/metabolism , Cell Line, Tumor , Drug Stability , Female , Humans , Immunotoxins/genetics , Immunotoxins/metabolism , Immunotoxins/pharmacokinetics , Mice , Mice, Inbred BALB C , Molecular Sequence Data , Neoplasms, Experimental/drug therapy , Neoplasms, Experimental/metabolism , Receptor, ErbB-2/biosynthesis , Receptor, ErbB-2/genetics , Recombinant Fusion Proteins/biosynthesis , Recombinant Fusion Proteins/genetics , Recombinant Fusion Proteins/pharmacokinetics , Ribonucleases/genetics , Ribonucleases/metabolism
16.
J Pept Sci ; 10(2): 92-102, 2004 Feb.
Article in English | MEDLINE | ID: mdl-14994987

ABSTRACT

Astins, antitumour cyclic pentapeptides, were isolated from the Aster tataricus. Their chemical structures, consist of a 16-membered ring system containing a unique beta,gamma-dichlorinated proline [Pro(Cl)2], other non-coded amino acid residues and a cis conformation in one of the peptide bonds. The astin backbone conformation, along with the cis peptide bond in which the beta,gamma-dichlorinated proline residue is involved, was considered to play an important role in their antineoplastic activities on sarcoma 180A and P388 lymphocytic leukaemia in mice, but the scope and potential applications of this activity remain unclear. With the aim at improving our knowledge of the conformational properties influencing the bioactivity in this class of compounds, new astin-related cyclopeptides were synthesized differing from the natural products by the presence of some non-proteinogenic amino acid residues: Aib, Abu, -(S)beta3-hPhe and a peptide bond surrogate (-SO2-NH-). The analogues prepared c(-Pro-Thr-Aib-beta3-Phe-Abu-), c[Pro-Thr-Aib-(S)beta3-hPhe-Abu], c[Pro-Abu-Ser-(S)beta3-hPhe psi(CH2-SO2-NH)-Abu] and c[Pro-Thr-Aib-(S)beta3-hPhe psi(CH2-SO2-NH)-Abu] were synthesized by classical methods in solution and tested for their antitumour effect. These molecules were studied by crystal-state x-ray diffraction analysis and/or solution NMR and MD techniques.


Subject(s)
Antineoplastic Agents/chemical synthesis , Antineoplastic Agents/pharmacology , Peptides, Cyclic/chemical synthesis , Peptides, Cyclic/pharmacology , Antineoplastic Agents/chemistry , Cell Line, Tumor , Crystallography, X-Ray , Drug Screening Assays, Antitumor , Humans , Hydrogen Bonding , Inhibitory Concentration 50 , Molecular Structure , Nuclear Magnetic Resonance, Biomolecular , Peptides, Cyclic/chemistry , Protein Structure, Tertiary , Temperature
17.
FASEB J ; 17(12): 1771-3, 2003 Sep.
Article in English | MEDLINE | ID: mdl-12958205

ABSTRACT

Stimulation of cannabinoid CB1 receptors by 2-methyl-arachidonyl-2'-fluoro-ethylamide (Met-F-AEA) inhibits the growth of a rat thyroid cancer cell-derived tumor in athymic mice by inhibiting the activity of the oncogene product p21ras. Here we report that Met-F-AEA also blocks the growth of tumors previously induced in nude mice by the s.c. injection of the same rat thyroid carcinoma cells. Met-F-AEA significantly inhibited, in tumors as well as transformed cells, the expression of the vascular endothelial growth factor, an angiogenetic factor known to be up-regulated by p21ras, as well as of one of its receptors, flt-1/VEGFR-1. The levels of the cyclin-dependent kinase inhibitor p27(kip1), which is down-regulated by p21ras, were instead increased by Met-F-AEA. All these effects were antagonized by the selective CB1 receptor antagonist SR141716A. Met-F-AEA inhibited in vitro the growth of a metastasis-derived thyroid cancer cell line more potently than a primary cancer cell line. Therefore, the hypothesis that CB1 receptor stimulation interferes not only with angiogenesis but also with metastatic processes was tested in a widely used model of metastatic infiltration in vivo, the Lewis lung carcinoma (3LL) in C57Bl/6 mice. Three weeks from the paw injection of 3LL cells, Met-F-AEA reduced significantly the number of metastatic nodes, in a way antagonized by SR141716A. Our findings indicate that CB1 receptor agonists might be used therapeutically to retard tumor growth in vivo by inhibiting at once tumor growth, angiogenesis, and metastasis.


Subject(s)
Carcinoma/drug therapy , Neovascularization, Pathologic , Receptors, Drug/metabolism , Angiogenesis Inducing Agents/metabolism , Angiogenesis Inhibitors/metabolism , Animals , Antineoplastic Agents/therapeutic use , Arachidonic Acids/therapeutic use , Cannabinoids/therapeutic use , Carcinoma/blood supply , Carcinoma/pathology , Carcinoma, Lewis Lung/drug therapy , Carcinoma, Lewis Lung/pathology , Cell Division/drug effects , Mice , Mice, Inbred C57BL , Mice, Nude , Models, Biological , Neoplasm Metastasis , Rats , Receptors, Cannabinoid , Signal Transduction , Thyroid Neoplasms/drug therapy , Thyroid Neoplasms/pathology , Tumor Cells, Cultured
18.
J Clin Endocrinol Metab ; 88(6): 2900-7, 2003 Jun.
Article in English | MEDLINE | ID: mdl-12788904

ABSTRACT

Bovine seminal ribonuclease (BS-RNase), a natural dimeric homolog of bovine pancreatic RNase (RNase A), and HHP2-RNase, an engineered dimeric form of human pancreatic RNase (HP-RNase), are endowed with powerful antitumor effects. Here we show that BS- and HHP2-RNases, but not monomeric RNase A, induce apoptosis of human thyroid carcinoma cell lines. RNase-induced apoptosis was associated with activation of initiation caspase-8 and -9. This was followed by activation of executioner caspase-3, leading to the proteolytic cleavage of poly(ADP-ribose) polymerase. The caspase inhibitor Z-Val-Ala-Asp-(OMe)-fluoromethylketone protected thyroid cancer cells from BS-RNase-induced apoptosis. RNase-triggered apoptosis and caspase activation were accompanied by reduced phosphorylation of Akt/protein kinase B (PKB), a serine-threonine kinase that when phosphorylated is able to deliver survival signals to cancer cells. BS-RNase antitumor effects in nude mice were accompanied by caspase activation and apoptosis. Because of the high selectivity of apoptotic effects for malignant cells, BS- and HHP2-RNase are promising tools for the treatment of aggressive thyroid cancer.


Subject(s)
Antineoplastic Agents/pharmacology , Apoptosis , Carcinoma/physiopathology , Caspases/metabolism , Endoribonucleases/pharmacology , Protein Serine-Threonine Kinases , Ribonuclease, Pancreatic/pharmacology , Thyroid Neoplasms/physiopathology , Amino Acid Chloromethyl Ketones/pharmacology , Animals , Caspase Inhibitors , Cysteine Proteinase Inhibitors/pharmacology , Humans , Mice , Mice, Nude , Phosphorylation/drug effects , Proto-Oncogene Proteins/metabolism , Proto-Oncogene Proteins c-akt , Tumor Cells, Cultured
19.
J Med Virol ; 69(2): 195-201, 2003 Feb.
Article in English | MEDLINE | ID: mdl-12683407

ABSTRACT

To investigate whether it is appropriate to assume comparability of hepatitis virus C (HCV)-RNA results across laboratories in multi-centre studies, nine laboratories of the European Paediatric HCV Network participated in an international proficiency study of HCV-RNA assays. A panel of 12 samples of different dilutions and genotypes was sent to each laboratory and tested with qualitative and/or quantitative HCV-RNA assays according to local procedures. Commercial assays were used in seven laboratories and in-house assays in two. All six laboratories in which a commercial qualitative assay was used were proficient, as were four of six runs (in five laboratories) in which a commercial quantitative assay was used. The proficiency of the laboratories where in-house assays were used could not be assessed according to the VQC definition because of differences in the methods used. Overall, there were several false-negative results, but only one false-positive result with a quantitative assay and none with a qualitative assay. The false-negative results may have implications for the diagnosis of infection, and highlight the need for an antibody test to be performed at 18 months to confirm the absence of infection. The results of qualitative assays were generally consistent across laboratories but it was difficult to evaluate and compare the results of quantitative assays. Multivariate analysis of data collected in multi-centre studies should therefore allow for centre and/or assay used.


Subject(s)
Hepacivirus/isolation & purification , Hepatitis C/diagnosis , Laboratories , Multicenter Studies as Topic/standards , Polymerase Chain Reaction/methods , RNA, Viral/blood , Child, Preschool , Europe , False Positive Reactions , Female , Hepacivirus/genetics , Hepatitis C/virology , Humans , Infant , Multicenter Studies as Topic/methods , Polymerase Chain Reaction/standards , Quality Control , Reagent Kits, Diagnostic , Reproducibility of Results , Sensitivity and Specificity
20.
Oncol Res ; 13(1): 25-35, 2002.
Article in English | MEDLINE | ID: mdl-12201671

ABSTRACT

We have previously shown that in vivo ras-transformed cell lines display natural doxorubicin resistance compared with the normal cells and that such resistance is accompanied by a plasma membrane depolarization. In this article we first extend the analysis of doxorubicin effect to other ras-transformed cell lines, which are characterized by an increasing degree of malignant phenotype. Rat thyroid ras-transformed cells are markedly resistant to doxorubicin and the degree of drug resistance correlates with the degree of cell malignancy. The lower amount of drug accumulated inside the malignant and resistant cells is a consequence of their constitutive depolarized membrane potential and may account for their lack of drug-induced apoptosis. Verapamil, a known modulator of drug resistance, is able to decrease the resistance of all the malignant cell lines, initially causing a higher incorporation of doxorubicin as a consequence of its ability to hyperpolarize the membrane potential. In resistant cells, verapamil is also able to alter the mitochondrial membrane potential allowing apoptosis. In conclusion, these studies demonstrate that ras transformation induces the natural resistance to doxorubicin of the malignant cells. We suggest that the most malignant and resistant cells, of metastatic origin, could be preferentially destroyed by manipulation of their membrane properties, and we confirm the possibility of overcoming drug resistance by the administration of verapamil also in P-gp170-nonexpressing cells.


Subject(s)
Cell Membrane/drug effects , Cell Transformation, Neoplastic , Doxorubicin/pharmacokinetics , Genes, ras , Verapamil/pharmacology , Animals , Apoptosis/drug effects , Cell Line , Cell Survival/drug effects , Cell Transformation, Neoplastic/drug effects , Drug Resistance, Neoplasm , Epithelial Cells/drug effects , Epithelial Cells/pathology , Intracellular Membranes/drug effects , Kinetics , Membrane Potentials/drug effects , Mitochondria/drug effects , Mitochondria/physiology , Rats , Thyroid Gland
SELECTION OF CITATIONS
SEARCH DETAIL
...